Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patient - StreetInsider.com
2/26/2022 12:00:00 AM4 yearsago
- Decision to use commercially supplied Idefirix® (imlifidase) in approved indication by the European Medicines Agency (EMA)1,2       …
- Decision to use commercially supplied Idefirix® (imlifidase) in approved indication by the European Medicines Agency (EMA)1,2          - Decision provides highly sensitized patient… [+9994 chars]
full article...